Public Release: 

Height influences risk of cardiovascular disease, diabetes, and cancer

Deutsches Zentrum fuer Diabetesforschung DZD

IMAGE

IMAGE: This infographic shoes that tall people have a lower risk for cardiovascular disease and type 2 diabetes, but a higher risk of cancer due to dietary and interacting factors such... view more

Credit: ©N. Stefan/DZD

February 02, 2016. Height is largely genetically determined, but in recent decades the height of children and adults has steadily increased throughout the world: In adulthood the children are almost always significantly taller than their parents. The largest increase in height in recent decades is found in the Netherlands. Dutch men are now 20 cm taller than they were 150 years ago. Interestingly, in the Netherlands the per capita consumption of milk and dairy products is the highest in the world.

These observations led the DZD scientists Professor Norbert Stefan and Professor Hans-Ulrich Häring of the Department of Internal Medicine IV in Tübingen and the Institute for Diabetes Research and Metabolic Diseases of Helmholtz Zentrum München at the University of Tübingen (IDM) and Professor Matthias Schulze of the German Institute of Human Nutrition in Potsdam (DIfE), in collaboration with Professor Frank Hu of the Harvard School of Public Health and Medical School in Boston, USA, to analyze the causes and medical effects of this increase in height.

Height influences risk of major non-communicable diseases

The study shows that height has an important impact on the mortality from certain common diseases, irrespective of body fat mass and other modulating factors. Previous studies have shown clearly that tall people, in comparison to short people, have a lower risk of cardiovascular disease and type 2 diabetes but have a higher cancer risk. "Epidemiological data show that per 6.5 cm in height the risk of cardiovascular mortality decreases by six percent, but cancer mortality, by contrast, increases by four percent," Professor Schulze said.

Multiple causes are suspected

The authors suspect that the increase in body height is a marker of overnutrition of high-calorie food rich in animal protein during different stages of growth. Thus, already in utero, lifelong programming might take place that until now has mainly been established for the insulin-like growth factor 1 and 2 and the IGF-1/2 system. Among other consequences, activation of this system causes the body to become more sensitive to insulin action, thus positively influencing the lipid metabolism. "Accordingly, our new data show that tall people are more sensitive to insulin and have lower fat content in the liver, which may explain their lower risk for cardiovascular disease and type 2 diabetes," Professor Stefan added. These findings fit in with published data that suggest that tall people have relative protection against disorders of the lipid metabolism. However, this activation of the IGF-1/2 system and other signaling pathways may be related to an increased risk of certain cancers, especially breast cancer, colon cancer, and melanoma because cell growth is permanently activated, the authors suspect. The result is an inverse association with the risk of cardiovascular disease and type 2 diabetes, but a positive association with the risk of cancer.

Conclusion: Height should be more of a consideration in prevention

The scientists advocate considering the factor growth and adult height more than hitherto in the prevention of the above-mentioned major diseases. In particular, physicians should be made more aware of the fact that tall people - although less often affected by cardiovascular disease or type 2 diabetes - have an increased risk of cancer. Hitherto, the importance of diet has been underestimated, especially during pregnancy and in children and adolescents.

###

German Center for Diabetes Research (DZD)

The German Center for Diabetes Research (DZD) is one of the six German Centres of Health Research. It brings together experts in the field of diabetes research and connects basic research, epidemiology and clinical application through its integrative research approach. The aim of the DZD is to make a significant contribution to the successful prevention, diagnosis and therapy of diabetes mellitus.

Members of the research network are Helmholtz Zentrum München - German Research Center for Environmental Health, the German Diabetes Center DDZ in Düsseldorf, the German Institute of Human Nutrition DIfE in Potsdam-Rehbrücke, the Institute for Diabetes Research and Metabolic Diseases of Helmholtz Zentrum München at the University of Tübingen and the Paul Langerhans Institute Dresden of Helmholtz Zentrum München at the University Hospital Carl Gustav Carus Dresden at TU Dresden, associate partners at the universities in Heidelberg, Cologne, Leipzig, Munich, and Lübeck as well as other project partners.

Source

Norbert Stefan, Hans-Ulrich Häring, Frank B Hu, Matthias B Schulze. Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. Lancet Diabetes & Endocrinology 2016 [epub ahead of print] http://dx.doi.org/10.1016/S2213-8587(15)00474-X

Media contact for the German Center for Diabetes Research (DZD)

Dr. Silvia Grote
German Center for Diabetes Research (DZD)
Ingolstädter Landstraße 1
85764 Neuherberg
Germany
Phone: +49 (0)89-3187-3971
grote@dzd-ev.de

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.